Advertisement

Topics

HARVEY NASH GROUP Company Profile

00:23 EDT 23rd October 2017 | BioPortfolio

Harvey Nash was founded in London in 1988. David Higgins, the current Executive Vice Chairman, was one of the original founders and still has a sizeable financial stake in the company. Early on, the management broadened the Group’s geographical coverage and increased the range of services, recognising the value this would add to the business in the longer term.

An IPO in April 1997 facilitated a fresh injection of capital into the business, fast tracking expansion into Europe, the USA and Asia. This was achieved through a mix of acquisitions and organic growth.

Today, Harvey Nash holds a unique position as the only truly global IT recruitment business listed on the London Stock Exchange with over 3,000 employees and contractors working across 28 offices worldwide

Location

13 Bruton Street
London
London
W1J 6QA
United Kingdom

Contact

Phone: 44 (0)20 7333 0033
Fax: 44 (0)20 7333 0032
Email: info@harveynash.com


News Articles [1063 Associated News Articles listed on BioPortfolio]

GENFIT – The NASH Education ProgramTM annonce le lancement de la première Journée Internationale d’Information sur la NASH, le 12 juin 2018

GENFIT — Thursday, July 13th 2017 at 5:19pm UTC GENFIT – The NASH Education ProgramTM annonce le lancement de la première Journée Internationale d’Information sur la NASH, le 12 ju...

Boehringer Ingelheim Partners with Target PharmaSolutions to Progress NASH Research

CHAPEL HILL, N.C., Oct. 19, 2017 /PRNewswire/ — TARGET PharmaSolutions, Inc., a real-world clinical data company, is pleased to announce that Boehringer Ingelheim International GmbH has entered ...

The NASH Education Program™: Key Insights from the First US Survey Commissioned by the NASH ...

Read more...

Bristol-Myers Squibb Extends Partnership with Target PharmaSolutions for TARGET-NASH

CHAPEL HILL, N.C, Oct. 12, 2017 /PRNewswire/ — TARGET PharmaSolutions, Inc., a real-world clinical data company, is pleased to announce that Bristol-Myers Squibb (BMY) has extended its strategic...

GENFIT ??? The NASH Education Programtm Announces The Launch Of The First International NASH Information Day On June 12, 2018: Save The Date!

  Life Sciences Jobs   ...

Harvey Fierstein Responds To Being Mistaken For Harvey Weinstein

Harvey Fierstein has been inadvertently thrust into a sexual harassment scandal that’s shaken up Hollywood.

Cecil McCrory’s Newly Released “Julia’s Adventures With Harvey and Tinker Belle: Julia Meets Harvey” is a Delightful Tale That Tells a Valuable Lesson for a Lifetime

(PRWEB) October 12, 2017 “Julia’s Adventures with Harvey and Tinker Belle: Julia Meets Harvey”: a charming narrative...

Women’s Health Group Is Funding Abortions for Harvey Victims

(New York Post) – A women’s health organization that is battling the state of Texas over proposed abortion legislation is offering fully paid procedures for Hurricane Harvey victims — and 15...

PubMed Articles [1869 Associated PubMed Articles listed on BioPortfolio]

The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids.

The histologic spectrum of nonalcoholic fatty liver disease (NAFLD) includes fatty liver (NAFL) and steatohepatitis (NASH), which can progress to cirrhosis in up to 20% NASH patients. Bile acids (BA) ...

Nation-wide trends in non-alcoholic steatohepatitis (NASH) in patients with and without diabetes between 2004-05 and 2014-15 in England.

There are no national studies evaluating the epidemiology of non-alcoholic steatohepatitis (NASH) in England. NASH is becoming an increasingly important health issue given the inexorable rise in obesi...

Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis.

Nonalcoholic steatohepatitis (NASH) is projected to be the leading cause of liver transplantation by 2020. Advanced fibrosis (stage F3-F4) on liver biopsy independently predicts all-cause and liver-re...

A Novel Role of Astrocyte Elevated Gene-1 (AEG-1) in Regulating Non-alcoholic Steatohepatitis (NASH).

Nonalcoholic steatohepatitis (NASH) is the most prevalent cause of chronic liver disease in the Western world. However, an optimum therapy for NASH is yet to be established mandating more in-depth inv...

Docosahexaenoic acid blocks progression of western diet-induced nonalcoholic steatohepatitis in obese Ldlr-/- mice.

Nonalcoholic fatty liver disease (NAFLD) is a major public health concern in western societies. Nonalcoholic steatohepatitis (NASH), the progressive form of NAFLD, is characterized by hepatic steatosi...

Clinical Trials [3296 Associated Clinical Trials listed on BioPortfolio]

Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH

CP-945598 is a potent and selective Cannabinoid-1 (CB1) receptor antagonist currently being developed for the treatment of obesity. CP-945598 is also being considered as a potential treat...

Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH

The primary objective of this study is the proof of mechanism and support of dose finding, together with the safety evaluation in patients with clinical evidence of NASH. To gain further ...

A 5-year Longitudinal Observational Study of Patients With Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH)

TARGET-NASH is a longitudinal observational cohort study of patients being managed for NAFLD or NASH in usual clinical practice. TARGET-NASH will create a research registry of patients wit...

Protocol for the Assessment of Variability in Histology and Gene Expression in Bariatric Surgery Patients.

It is known that a vast majority of patients seeking a bariatric surgery weight reduction procedure have non-alcoholic fatty liver disease (NAFLD), while a smaller subset of patients withi...

Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH

The purpose of the present study is to assess the effects of LMB763 with respect to safety, tolerability, and on markers of liver inflammation in patients with NASH

Companies [1602 Associated Companies listed on BioPortfolio]

HARVEY NASH GROUP

Harvey Nash was founded in London in 1988. David Higgins, the current Executive Vice Chairman, was one of the original founders and still has a sizeable financial stake in the company. Early on, the m...

Nash Finch Company

Patricia Nash

The quintessential embodiment of style, form and function, Patricia Nash Designs creates handbags and accessories that are made of beautiful, vegetable tanned Italian leather. The...

Harvey & Company LLC

Harvey & Company has a long track record of successful investments and acquisitions across a variety of manufacturing, business service and distribution sectors. Our success is based on the recognitio...

North American Specialty Hospital

Headquartered in Denver, NASH is a US majority-owned and managed enterprise. Incorporating US physicians in its service delivery, NASH is designed to provide pre-operative and pos...

More Information about "HARVEY NASH GROUP" on BioPortfolio

We have published hundreds of HARVEY NASH GROUP news stories on BioPortfolio along with dozens of HARVEY NASH GROUP Clinical Trials and PubMed Articles about HARVEY NASH GROUP for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of HARVEY NASH GROUP Companies in our database. You can also find out about relevant HARVEY NASH GROUP Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record